AstraZeneca PLC (AZN)
NYSE:AZN
Want to see AZN full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.49Last Year’s EPS
2.17Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted robust commercial momentum and strong R&D execution: double-digit growth in oncology and rare disease, four positive Phase III readouts (including tozorakimab and efzimfotase alfa), high core gross margins and reiterated full-year guidance. These positives are tempered by clear near-term headwinds—declines in biopharmaceutical/CVRM revenues driven by LOE and pricing changes (VBP), selective clinical misses or non-significant primary endpoints in parts of the rare/metabolic and COPD extension data, increased capital and milestone outflows, and a rise in net debt. On balance the company presented multiple high-value growth drivers and a rich 2026 catalyst calendar that outweigh the operational and access challenges discussed.Company Guidance
Total Revenue and Profit Growth
Total revenue grew 8% in Q1 2026; core operating profit increased 12%, and core EPS rose 5% to $2.58 (growth tempered by a low prior-period tax rate).
Strong Oncology Performance
Oncology revenues grew 16% to $6.8 billion with notable brand performances: Tagrisso +5% to $1.8 billion, Imfinzi +30% (Imfinzi & Imjudo combined +28%), Calquence +17% to >$900 million, and Enhertu +34% (annualizing as a ~$5 billion brand on an alliance view).
Biopharmaceutical Growth Areas
Respiratory & Immunology up 7% to $2.3 billion. Key brands: Fasenra +11% to $483 million (emerging markets +63% in China uptake), Breztri +13% to $353 million (first asthma label expansion), Tezspire +34% to $303 million, and Saphnelo +24% to $171 million.
Rare Disease Momentum and New Assets
Rare Disease revenue rose 15% to $2.4 billion. Ultomiris grew 18% and Strensiq grew 43%. Efzimfotase alfa reported positive Phase III data and is positioned for broad adoption with an estimated peak-year sales opportunity of $3–$5 billion.
Pipeline and R&D Delivery
Four positive high-value Phase III program readouts announced in early 2026 (including tozorakimab and efzimfotase alfa). Number of active clinical trials +10% and patient enrollment +30% year-on-year; ongoing investment in transformative technologies (cell therapies, T-cell engagers).
High Core Gross Margin and Operating Leverage
Core gross margin of 83% in Q1 with expectation of stable to slightly higher margin for the full year; operating leverage contributed to stronger operating profit growth.
Solid Cash Generation and Capital Allocation
Operating cash flow was $3.4 billion in the quarter (slight decline versus prior year due to one-time milestone in Q1 2025), CapEx $600 million supporting multiyear manufacturing investments, and the company reiterated mid- to high-single-digit revenue growth and low-double-digit core EPS growth guidance at CER for the full year.
Tozorakimab: Potential First-in-Class COPD Biologic
Tozorakimab achieved statistically significant, clinically meaningful reductions in annualized moderate-to-severe exacerbations across pivotal trials (OBERON, TITANIA, MIRANDA) with favorable tolerability; potential addressable COPD biologic population highlighted and regulatory submissions planned.
AZN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AZN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $186.68 | $185.20 | -0.79% |
Feb 10, 2026 | $186.05 | $191.39 | +2.87% |
Nov 06, 2025 | $158.19 | $167.24 | +5.72% |
Jul 29, 2025 | $141.62 | $147.88 | +4.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AstraZeneca PLC (AZN) report earnings?
AstraZeneca PLC (AZN) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is AstraZeneca PLC (AZN) earnings time?
AstraZeneca PLC (AZN) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AZN EPS forecast?
AZN EPS forecast for the fiscal quarter 2026 (Q2) is 2.49.